versión imprimible
 
 

Triple Negative Breast Cancer Drug Development Summit

Evvnt Promotion / evvnt
-
28.04.2021 - 29.04.2021  Virtual
Time: 08:00 to 16:00
 
Temas de la conferencia
This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.

Breast cancer (BC) is the most common solid tumor in women, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence.
Organizador profesional (PCO)
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/729098-2?pid=4832

Speakers: Alison L. Hannah, Senior Vice President and Chief Medical Officer, CytomX Therapeutics, Angus Sinclair, VP Immuno-Oncology, IGM Biosciences, and more.
 

Información e inscripción:

https://go.evvnt.com/729098-1?pid=4832
Mr. Customer Services
 
Categorías
Oncología
Idioma
Inglés
Cuota del Congreso
Conference Only (Drug Developer Pricing): USD 1999.00, Conference Only (Service Provider Pricing): USD 2499.00, Conference Only (Academic Pricing): USD 1799.00
Los participantes esperaban
1000 - 1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Alumni Club Medizinische Universität WiennewTreeAnästhesie in Entwicklungsländern e. V.Österreichisches Rotes KreuzCenter of ExcellenceÖsterreichische Gesellschaft für Public HealthCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioHilfswerk Austria